Status as of October 12, 2026. This area changes fast, so check the sources below for updates.
In July 2026, an FDA advisory group met to review peptides for the 503A bulk drug substances list. The group is called the Pharmacy Compounding Advisory Committee, or PCAC. The list matters because it names the ingredients that compounding pharmacies can legally use to make custom prescriptions.
FDA’s own career scientists reviewed the peptides first. They recommended against adding all seven that were under consideration. Their concerns included limited human data, safety, purity, and how well the compounds are characterized.
The committee heard that presentation, plus public testimony. Then it voted differently. It recommended six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon.
So the agency’s staff said no and its advisors said yes. That split is why this story got so much attention.
It does not mean these peptides are FDA approved. Approval is a different process. It requires clinical trials showing a drug is safe and works for a specific use.
It also does not change the bulks list. The committee is advisory. FDA does not have to follow its recommendation. It can accept it, turn it down, ask for more information, or wait.
You may also see the term “Category 1” in news coverage. FDA used categories as an interim enforcement tool for compounding. Category 1 status is not approval either. It does not mean a peptide has been shown to be safe or effective. A favorable PCAC vote also does not automatically put a peptide in Category 1.
If FDA decides to move forward, it has to go through formal rulemaking. That means a proposed rule, a public comment period, and then a final rule. Only after that could pharmacies legally compound these six peptides under the list.
There is no set deadline. One law firm that follows this area points to an earlier case where a proposed rule for ten substances came out in December 2016 and was not finalized until February 2019. Other commentators have estimated 12 to 24 months for this one. Nobody can say for sure.
In the meantime, nothing has changed on paper. Anyone who tells you these six are now cleared for compounding is getting ahead of the facts.
Both sides were looking at the same thin record. Most of the research on these peptides is in animals or cells. Human data is limited. Some of it is small studies and some is anecdotal.
FDA’s scientists treated that gap as a reason to wait. The committee appears to have weighed other things, including public testimony and the fact that many people are already using these products through unregulated “research use only” sellers. Supporters of the vote argue that regulated compounding with testing and a prescription would be safer than that.
Both arguments are reasonable. They are just answering different questions. One asks whether the evidence is strong enough. The other asks what happens if people use these products anyway.
If you are curious about any of these peptides, it helps to bring good questions. A few to consider:
A committee recommended six peptides. FDA’s own scientists disagreed. The agency has not made a final decision, and any change would take a formal rulemaking process that could run well over a year.
Until then, these are still unapproved compounds with limited human evidence. That may change. We will update this page when FDA acts.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.